IGC Pharma, Inc. today announced a Master Cooperation Agreement with the University of Los Andes for the development and adoption of generative AI solutions into the Company’s drug identification, development, and clinical trial processes. IGC Pharma will be focused on advancing various AI initiatives including:
- Streamlining clinical trial efficiency: IGC Pharma’s leading drug asset, IGC-AD1, is currently in Phase 2 clinical trials for the treatment of agitation related to symptoms of Alzheimer’s disease, with four additional assets progressing towards clinical trials. The Company believes that the integration of AI algorithms into clinical trials can significantly enhance trial efficiency including progress, cost reduction, and data analysis.
- Enhancing early detection methods for Alzheimer’s disease: Early detection and diagnosis of Alzheimer’s disease is a key factor in effective treatment. According to the Alzheimer’s Association, as many as 50 percent of people with Alzheimer’s or a similar form of dementia do not receive a formal diagnosis. By integrating AI algorithms into the evaluation process to analyze clinical trial and other data, the Company expects to reduce the risk of false negatives in the early diagnosis of Alzheimer’s disease and greatly improve the odds of successful treatment in the process, although there can be no assurance thereof.
- Improving drug interaction analysis: The integration of AI algorithms into drug interaction analysis can create a new methodology for doctors to quickly analyze interactions between formulations including IGC-AD1, the Company’s THC-based drug formulation for the treatment of agitation from symptoms related to Alzheimer’s disease, and anti-psychotics and other medications commonly used in the treatment of Alzheimer’s.
Ram Mukunda, Chief Executive Officer of IGC Pharma, commented, “We are very pleased to be partnering with the University of Los Andes to further our AI initiatives through the development and adoption of AI algorithms that have the potential to significantly enhance the treatment of Alzheimer’s disease and other chronic illnesses. We believe that generative AI solutions can have transformative applications for our Company and the drug development industry overall, and we are committed to investing in and driving AI algorithm development and adoption. As we execute our strategic initiatives and position IGC Pharma at the forefront of AI adoption, we expect to gain a distinct competitive advantage as we streamline clinical trial efficiencies, enhance early detection of Alzheimer’s, improve methodologies for the analysis of drug interaction, and improve the treatment experience for patients, should our AI algorithms prove successful.”
The Company is currently pursuing five drug assets targeting the treatment of agitation related to symptoms of Alzheimer’s disease. These assets include IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, all of which are currently in different stages of clinical trials and development.